Background/Aim: If VEGF inhibitors contribute to an increase in D-dimer levels, they may adversely affect the diagnosis of venous thromboembolism (VTE). Consequently, this retrospective study examined the effects of VEGF inhibitors on D-dimer levels in colorectal cancer patients. Patients and Methods: A total of 104 colorectal cancer patients who received chemotherapy, were included in this study. To perform D-dimer analysis, patients were divided into two analysis targets: patients with VTE and without VTE. Statistical analysis included a natural logarithmic transformation of D-dimer data. Results: In the D-dimer analysis of non-VTE patients, the natural logarithm D-dimer mean difference was -0.186, with a 95% CI of -0.525 to 0.154. The upper limit of the 95%CI (0.154) did not exceed the non-inferiority margin (Δ) of 0.199, and therefore met the non-inferiority criteria. Conclusion: VEGF inhibitors don't contribute to increased D-dimer levels in colorectal cancer patients without VTE.
CITATION STYLE
Toshima, H., Ikusue, T., Hisamatsu, A., Kobayashi, K., Ishida, H., & Shimada, K. (2019). VEGF Inhibitors do without venous thromboembolism not increase d-dimer levels in colorectal cancer patients: a retrospective non-inferiority analysis. In Vivo, 33(6), 2117–2123. https://doi.org/10.21873/invivo.11712
Mendeley helps you to discover research relevant for your work.